



Supplementary Figure 12. Mint3 promotes tumor malignancy of pancreatic cancer.

- (a) Tumor growth of orthotopically inoculated control (shLacZ), Mint3-depleted (shMint3), or both Mint3 and FIH-1 depleted (shMint3 + shFIH-1) AsPC-1 cells in the pancreas of immunodeficient mice (n = 7). Error bars indicate SD. $**p < 0.01$ (Mann-Whitney U test).
- (b) mRNA levels of EMT-related genes in pancreatic tumors of control and Mint3-depleted AsPC-1 cells. Expression levels were normalized to *ACTB*. Error bars indicate SD (n = 6 per group). $*p < 0.05$, $**p < 0.01$ (Mann-Whitney U test). nd, not detected.
- (c) Immunohistochemical analysis of E-cadherin, N-cadherin, Slug, and vimentin in tumors of control (shLacZ) and Mint3-depleted (shMint3) AsPC-1 cells.
- (d) *APBA3* (encoding Mint3) and *SKP2* mRNA levels in human pancreatic cancer from the Badea 78 dataset of The Cancer Genome Atlas database. The correlation factor was $R = 0.319$, and $p = 4.4 \times 10^{-3}$ (one-way ANOVA).
- (e) Kaplan-Meier plot analysis of overall survival of pancreatic cancer patients with Mint3 high (n = 32, blue) and low (n = 64, red) expression from the Bailey 96 dataset of R2 database. $p = 0.036$ (log-rank test).